TSE:GEN - GeneNews Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.06 -0.01 (-14.29 %)
(As of 01/15/2019 04:00 PM ET)
Previous CloseC$0.07
Today's RangeC$0.06 - C$0.07
52-Week RangeC$0.03 - C$0.18
Volume991,522 shs
Average Volume1.08 million shs
Market CapitalizationN/A
P/E Ratio-1.62
Dividend YieldN/A
BetaN/A
GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is based in Richmond Hill, Canada.

Receive GEN News and Ratings via Email

Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+1-905-7392030

Debt

Current Ratio0.08
Quick Ratio0.01

Price-To-Earnings

Sales & Book Value

Annual SalesC$169,018.00
Price / Sales50.97
Cash FlowC$0.01 per share
Price / Cash Flow8.00
Book ValueC($0.04) per share
Price / Book-1.67

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees16
OptionableOptionable

GeneNews (TSE:GEN) Frequently Asked Questions

What is GeneNews' stock symbol?

GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN."

How were GeneNews' earnings last quarter?

GeneNews Ltd (TSE:GEN) announced its earnings results on Wednesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.13 million during the quarter. View GeneNews' Earnings History.

When is GeneNews' next earnings date?

GeneNews is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for GeneNews.

Has GeneNews been receiving favorable news coverage?

Media coverage about GEN stock has been trending somewhat positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GeneNews earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days.

Who are some of GeneNews' key competitors?

Who are GeneNews' key executives?

GeneNews' management team includes the folowing people:
  • Mr. James R. Howard-Tripp, Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D., Co-Founder
  • Mr. Warren Whitehead, Chief Accountant (Age 67)
  • Mr. David Suria, Sr. Scientist

How do I buy shares of GeneNews?

Shares of GEN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is GeneNews' stock price today?

One share of GEN stock can currently be purchased for approximately C$0.06.

What is GeneNews' official website?

The official website for GeneNews is http://www.genenews.com.

How can I contact GeneNews?

GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030.


MarketBeat Community Rating for GeneNews (TSE GEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote "Outperform" if you believe GEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel